CompletedInterventionalPhase 3Updated Nov 19, 2021
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery | NCT01605942 | Trialant
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
ClinicalTrials.gov ID
NCT01605942
Lead Sponsor
AllerganINDUSTRY
Overall Status
Terminated
Study Type
Interventional
Phase
Phase 1
Enrollment
8Actual
Last Update Posted
Jul 1, 2015Estimated
Start Date
Jun 2012
Primary Completion Date
Sep 2012Actual
Completion Date
Sep 2012Actual
Brief Summary
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
Cataract
Dexamethasone Drug Delivery System
Placebo Drug Delivery System
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Planned single cataract extraction with lens implant
Best-corrected visual acuity of 20/200 or better in the opposite eye
Exclusion Criteria:
Glaucoma or history of intraocular hypertension in the study eye
History of chronic ocular allergy in the last year requiring treatment
Scheduled for cataract surgery in the non-study eye during study participation